Cogent Biosciences
Last updated: November 14, 2025
CEO - Andrew Robbins
Country: USA | Funding: $1.6B (+)
Founded: 2014
Website: https://www.cogentbio.com/
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
Founded: 2014
Website: https://www.cogentbio.com/
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
